Divestitures |
12 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Divestitures [Abstract] | |
| Divestitures | NOTE B – DIVESTITURES Avoca business sale On March 31, 2025, Ashland completed the sale of its Avoca business to Mane SA. Proceeds from the sale were $16 million, net of transaction costs. Ashland recorded an impairment charge of $183 million ($1 million allocated to goodwill, $134 million to other intangible assets, $33 million to property, plant and equipment, $14 million to operating lease assets, net and $1 million to other current assets) within the loss on divestitures, net caption of the Statement of Consolidated Comprehensive Income (Loss) for the year ended September 30, 2025. The impairment charge includes the impact of the related inside tax basis differences associated with the impaired assets. The tax benefit associated with the sale is included within the income tax expense (benefit) caption of the Statement of Consolidated Comprehensive Income (Loss) for the year ended September 30, 2025. See Note K for tax details associated with the transaction. Ashland also recorded a pre-tax gain on sale of $8 million following the completion of this divestiture, mainly related to working capital movements, within the loss on divestitures, net caption of Statement of Consolidated Comprehensive Income (Loss) for the year ended September 30, 2025. The Avoca business was included within Ashland's Personal Care reportable segment. Ashland determined this transaction did not qualify for discontinued operations treatment since it neither represented a strategic shift nor did it have a major effect on Ashland's operations and financial results. Nutraceuticals business sale On August 30, 2024, Ashland completed the sale of its Nutraceuticals business to Turnspire Capital Partners LLC. Proceeds from the sale were $26 million, net of transaction costs. Ashland recorded a $99 million impairment charge primarily related to allocated goodwill of $17 million, other intangible assets of $69 million and property, plant and equipment of $13 million within the loss on divestitures, net caption of the Statement of Consolidated Comprehensive Income (Loss) for the year ended September 30, 2024. The impairment charge includes the impact of the related inside tax basis differences associated with the impaired assets. The tax benefit associated with the sale is included within the income tax expense (benefit) caption of the Statement of Consolidated Comprehensive Income (Loss) for the year ended September 30, 2024. See Note K for tax details associated with the transaction. Ashland also recorded a pre-tax loss on sale of $8 million following the completion of this divestiture, mainly related to working capital movements, within the loss on divestitures, net caption of Statement of Consolidated Comprehensive Income (Loss) for the year ended September 30, 2024. The loss on divestitures, net caption also includes a reserve of $7 million for foreign value added taxes ("VAT") associated with the entities transferred within the Statement of Consolidated Comprehensive Income (Loss) for the year ended September 30, 2024. The Nutraceuticals business was included within Ashland's Life Sciences reportable segment. Ashland determined this transaction did not qualify for discontinued operations treatment since it neither represented a strategic shift nor did it have a major effect on Ashland's operations and financial results. Other corporate assets During the year ended September 30, 2026, Ashland completed the sale of two excess land properties with a net book value of $3 million. Ashland received net proceeds of $6 million and recorded a pre-tax gain of $3 million within the loss on divestitures, net caption of the Statement of Consolidated Comprehensive Income (Loss) during the year ended September 30, 2026. Ashland also recorded a $2 million pre-tax gain related to excess land property termination fee and a $13 million pre-tax loss related to the recognition of Argentina foreign currency cumulative translation adjustment due to the liquidation of Ashland's Argentina subsidiary within the loss on divestitures, net caption of the Statement of Consolidated Comprehensive Income (Loss) during the year ended September 30, 2026. During the year ended September 30, 2025, Ashland completed the sale of two excess land properties with a net book value of zero. Ashland received net proceeds and recorded a pre-tax gain of $15 million within the loss on divestitures, net caption of the Statement of Consolidated Comprehensive Income (Loss) during the year ended September 30, 2025. |